Bioinspired carbon monoxide delivery using artificial blood attenuates the progression of obliterative bronchiolitis via suppression of macrophage activation by IL-17A.
Animals
Blood Substitutes
/ administration & dosage
Bronchiolitis Obliterans
/ drug therapy
Carbon Monoxide
/ administration & dosage
Disease Models, Animal
Disease Progression
Drug Delivery Systems
Epithelial-Mesenchymal Transition
Hemoglobins
/ pharmacology
Interleukin-17
/ metabolism
Liposomes
Macrophage Activation
Mice
Mice, Inbred C57BL
Trachea
/ transplantation
Transforming Growth Factor beta
/ metabolism
Carbon monoxide
Drug delivery system
Fibrosis
Liposome
Obliterative bronchiolitis
Orthotopic tracheal transplantation
Journal
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V
ISSN: 1873-3441
Titre abrégé: Eur J Pharm Biopharm
Pays: Netherlands
ID NLM: 9109778
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
19
07
2021
revised:
28
10
2021
accepted:
28
11
2021
pubmed:
6
12
2021
medline:
22
3
2022
entrez:
5
12
2021
Statut:
ppublish
Résumé
Carbon monoxide (CO) is expected to attenuate the progression of obliterative bronchiolitis (OB), which is a serious complication after lung transplantation. However, issues in terms of feasible exogenous CO supply, such as continuousness and safety, remain unsolved. Here, we applied nano red blood cells, namely hemoglobin vesicles (Hb-V), as a CO cargo based on the biomimetic concept and investigated the therapeutic potential of CO-loaded Hb-V on OB in orthotopic tracheal transplant model mice. The CO-loaded Hb-V was comprised of negatively charged liposomes encapsulating carbonylhemoglobin with a size of ca. 220 nm. The results of histological evaluation showed that allograft luminal occlusion and fibrosis were significantly ameliorated by treatment with CO-loaded Hb-V compared to treatment with saline, cyclosporine, and Hb-V. The therapeutic effects of CO-loaded Hb-V on OB were due to the suppression of M1 macrophage activation in tracheal allografts, resulting from decreased IL-17A production. Furthermore, the expression of TNF-α and TGF-β in tracheal allografts was decreased by CO-loaded Hb-V treatment but not saline and Hb-V treatment, indicating that CO liberated from CO-loaded Hb-V inhibits epithelial-mesenchymal transition. These findings suggest that CO-loaded Hb-V exerts strong therapeutic efficacy against OB via the regulation of macrophage activation by IL-17A and TGF-β-driven epithelial-mesenchymal transition.
Identifiants
pubmed: 34864198
pii: S0939-6411(21)00341-6
doi: 10.1016/j.ejpb.2021.11.011
pii:
doi:
Substances chimiques
Blood Substitutes
0
Hemoglobins
0
Interleukin-17
0
Liposomes
0
Transforming Growth Factor beta
0
Carbon Monoxide
7U1EE4V452
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
43-51Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.